Abstract
Rhenium compounds have shown anti-cancer properties against many different types of cancer cell lines; however, the cellular signaling mechanisms involved in the cytotoxic properties of rhenium-based compounds were never deciphered or reported. In this manuscript, we report the results of an investigation done by RNA sequencing of rhenium treated A549 lung cancer cell lines along with an untreated vehicular control, analyzed by the Ingenuity Pathway Analysis (IPA) software system to decipher the core canonical pathways involved in rhenium induced cancer cell death. A549 EMT lung cancer cell lines were treated with rhenium ligand (Tricarbonylperrhenato(bathocuproine)rhenium(I), PR7) for seven days along with vehicular control. RNA was isolated from the treated and control cells and sequenced by a commercial company (PrimBio Corporation). The RNA sequencing data was analyzed by the INGNUITY software system and the core canonical pathways involved with differential gene expression were identified. Our report is showing that there are several cellular pathways involved in inducing cell death by rhenium-based compound PR7.
Highlights
We report the results of an investigation done by RNA sequencing of rhenium treated A549 lung cancer cell lines along with an untreated vehicular control, analyzed by the Ingenuity Pathway Analysis (IPA) software system to decipher the core canonical pathways involved in rhenium induced cancer cell death
A549 epithelial mesenchymal transition (EMT) lung cancer cell lines were treated with rhenium ligand (Tricarbonylperrhenato(bathocuproine)rhenium(I), PR7) for seven days along with vehicular control
Performing a MTT assay on A549 cells exposed to 1 μM PR7 showed an increase in cell death compared to cells exposed to DMSO alone as a vehicular control
Summary
We treated the vimentin knock in A549 lung cancer cell lines with PR7 after inducing EMT by TGF beta treatment and determined the cytotoxic effects of the drug by MTT assay technique. The RNA was sequenced at a commercial RNA sequencing laboratory (PrimBio, LLC, USA) This sequencing data was analyzed by the INGENUITY (IPA) software licensed from Qiagen Corporation, USA, to identify the potential effects of PR7 on gene expression and cellular signaling. In this manuscript, we report four core cellular canonical pathways that IPA reported and deciphered the differential gene expression due to the rhenium ligand treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
